Lv5
1110 积分 2024-03-09 加入
Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn’s Disease Patients with Prescription Claims for Ustekinumab in the USA
18天前
已完结
Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Australian National IBD Cohort (PANIC) study
18天前
已完结
Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
18天前
已完结
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease
18天前
已完结
IL-23 inhibition for chronic inflammatory disease
23天前
已完结
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
23天前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
25天前
已完结
The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease
5个月前
已完结
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
5个月前
已完结
P1167 Treatable traits (TTs) approach in the management of Inflammatory Bowel Disease: a new concept
5个月前
已完结
皖公网安备34019202002308
